1 / 64

Indonesia Pharmaceutical Market Analysis

This report presents a strategic analysis of the Indonesia Pharmaceutical Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Indonesia Pharmaceutical Market, and offers unmatched value, accuracy, and expert insights.

Insights10
Download Presentation

Indonesia Pharmaceutical Market Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sample Report Indonesia Pharmaceutical Market Analysis June 2024

  2. This report presents a strategic analysis of the Indonesia Pharmaceutical Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Indonesia Pharmaceutical Market, and offers unmatched value, accuracy, and expert insights.

  3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2023 Forecast Period 2024-2030 Market Overview, Size & Forecasting, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Currency Conversion 1 IDR = 0.0000608961 USD Research Approach Secondary Research (90%), Primary Research (10%) 3 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  4. Table of Content CONTENT PG. NO. 08-15 1. Market Overview 1.1 Indonesia Pharmaceutical Market Overview 1.2 Pharmaceutical Market Overview: Global 1.3 Demographic Overview: Indonesia 1.4 Economic Overview: Indonesia 1.5 Pharmaceutical Market Overview: Indonesia 1.6 Healthcare Overview: Indonesia 1.7 Budget of Indonesia Government for Public Insurance 16-17 2. Epidemiology 2.1 Prevalence of various disease in Indonesia 19-24 3. Market Size and Forecasting 3.1 Indonesia Pharmaceutical Market Size and Forecasts 3.2 Snapshot of Indonesia Pharmaceutical Market Segmentation 4 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  5. Table of Content CONTENT PG. NO. 3.2.1 Market Segmentation: By Therapy Area 3.2.2 Market Segmentation: By Product Type 3.2.3 Market Segmentation: By Molecule Type 25-30 4. Market Dynamics 4.1 Snapshot Of Market Growth Drivers And Restraints 4.2 Market Growth Drivers 4.2.1 Increased consumer buying power is a primary driver for growing pharmaceutical demand 4.2.2 Indonesia is experiencing an increase in prevalence of various lifestyle related diseases 4.2.3 Government is implementing various Policies and to improve healthcare service availability 4.3 Market Growth Restraints 4.3.1 Local player are Highly dependent on import of Active Pharmaceutical Agent (API) for drug development 4.3.2 Lack of human resource and limited Healthcare Infrastructure in rural areas is limiting market potential 31-38 5. Competitive Landscape 5.1 Key Players in Indonesia Pharmaceutical Market 5 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  6. Table of Content CONTENT PG. NO. 39-44 6. Regulatory and Reimbursement Landscape 6.1 Regulatory Landscape in Indonesia 6.2 Reimbursement Scenario in Indonesia 6.3 Reimbursement Process 6 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  7. Indonesia Pharmaceutical Market Analysis 1. Market Overview

  8. 1.1 Pharmaceutical Market Overview Pharmaceutical market includes discovery, development, production, marketing, and sales of medications ▪ It involves various stakeholders such as pharmaceutical companies, biotechnology companies and regulatory agencies ▪ Primary goal of pharmaceutical market is to provide effective, safe, and affordable medications to treat, prevent, and manage diseases ▪ Pharmaceutica Market structure: Pharmaceutical Market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Anti-Hypertensive Drugs, Lipid-Lowering Agents and Other Pharmaceuticals ▪ It includes generic drug, branded drug, Vaccines, biosimilars, and orphan drugs ▪ Government bodies responsible for overseeing the safety, efficacy, and quality of drugs. Major agencies include the FDA (US), EMA (Europe), and others globally ▪

  9. 1.2 Pharmaceutical Market Overview: Global (1/2) 67.60% Revenue Contributed by Branded Drug in 2022 Global Pharmaceutical Market Revenue 2022-2029 (In $Bn) 1454 17.07% Revenue contributed by Cancer drug in 2022 1389 1324 1262 1207 1155 1098 1096 37% North America market share in 2022 742 Abbreviated New Drug Application (ANDA) Approved in 2022 2022 2023 2024 2025 2026 2027 2028 2029 Sources: 9 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  10. 1.2 Indonesia Pharmaceutical Market Overview: Global (2/2) Indonesia Market ~$xx Bn Market Illustrative Illustrative 10 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  11. 1.3 Economic Overview: Indonesia GDP of Indonesia (In $Bn), (2023-2029) Population of Indonesia (In Mn), (2023-2029) 291.9 289.62 2194.82 2035.96 287.29 1886.12 1746.6 284.9 1613.9 1475.69 282.46 1371.17 279.97 277.43 2023 2024F 2025F 2026F 2027F 2028F 2029F 2023 2024F 2025F 2026F 2027F 2028F 2029F Population Split (2023) Median age in Indonesia is 29.9 years which is lower than global median age Country's population in global share is 3.45% and it is increasing at a rate of 0.82% Life expectancy of female is 73.3 years and for male it is 69.0 years 59.1% of the population of Indonesia is urban Top 3 largest cities are Indonesia are Jakarta, Surabaya, Medan. ▪ By Gender By Age Group ▪ 7% 0-14 ▪ 25% 15-64 Male Female ▪ 65+ 68% ▪ Illustrative Illustrative 11 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  12. 1.4 Indonesia Pharmaceutical Market Overview: Indonesia Government Expenditure on Healthcare (in $Bn) ), (2023-2029) 70% Revenue Contributed by Branded Drug in 2022 17.07% Revenue contributed by Cancer drug in 2022 70% Local player market share in 2022 90% Universal Health Insurance coverage in 2022 2023 2024F 2025F 2026F 2027F 2028F 2029F Illustrative Illustrative 12 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  13. 1.5 Healthcare Overview: Indonesia Public Healthcare Private Healthcare Universal Coverage: Indonesia government universal healthcare program, known as JKN-KIS, was first implemented in early January 2014 and has already covered over 90% of the country's population Complimentary: While public healthcare covers most needs, some people opt for private health insurance for additional benefits, such as shorter waiting time, specialist care or access to a wider range of treatments ▪ ▪ Funding: Funded through Central government, State government, Employers and Individual Funding: Self-funded or employer ▪ ▪ Coverage: Range of services, treatments, depends on insurance plan. Majority of private health insurance schemes provides benefits for hospitalization, ambulances and medicines ▪ Facilities: Community health centres (CHCs), known as puskesmas, are generally available at the sub-district level for 30,000 people on average. There are about 10,203 puskesmas that form the backbone of the country’s health delivery system ▪ Coverage: Basic medical services, hospitalization, some medications ▪ 13 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  14. 1.6 Budget of Indonesia Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 In Billions Of Dollars Medicare 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% As % Of GDP National Health Expenditures (NHE) grew 2.7% to $4.3 Tn in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 Bn in 2021, or 21% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 Bn in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 Bn in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 Bn, or 14% of total NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 Bn in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 Bn in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 Bn in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 14 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  15. 1.7 Top Developments in Indonesia Latest Deals in Indonesia Company Name Type Year Key Pointers Kalbe Farma acquired PT Aventis Pharma, an Indonesian subsidiary of Sanofi, for an undisclosed amount. This deal is aimed at expanding Kalbe Farma product portfolio and strengthening its position in the market​ Kalbe Farma signed a share sale and purchase agreement with Alliance Pharma Co. to expand its therapeutic classes in the fields of cardiology, general prescription drugs, and oncology ▪ Acquisition 2023 ▪ Pharos signed a distribution agreement with PT Medikon Prima Laboratories, a prominent manufacturer of ethical and over-the-counter products in Indonesia Pharos has planned a significant increase in manufacturing capacity through the construction of several new factories that will come on line, in stages, in the next two years ▪ Agreement 2022 ▪ Illustrative Illustrative 15 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  16. Indonesia Pharmaceutical Market Analysis 2. Epidemiology

  17. 2.1 Prevalence of various disease in Indonesia Disease Mortality in Indonesia (2023) 40.3% Prevalance of hypertnesion in adult 385 Number of TB cases per year per 100,000 population Cardiovascular Diseases Diabetes Respiratory Diseases Cancer 2.96 Number of new malaria cases per 1000 population at risk 11.2% Adults with a body mass index (BMI) of 30 kg/m2 or higher others 40% Tobacco use prevalence among 15 years and older 0.09 Number of new HIV infections per 1000 uninfected population Infant mortality rate for Indonesia in 2022 was 16.518 deaths per 1000 live births Life expectancy at birth (years) has improved by 1.09 years from 67.2 years in 2000 to 68.3 years in 2022 ▪ ▪ Illustrative Illustrative 17 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  18. Indonesia Pharmaceutical Market Analysis 3. Market Size and Forecasting

  19. 3.1 Indonesia Pharmaceutical Market Size and Forecasts Indonesia Pharmaceutical Market Forecast, 2023-2030 2023 2024F 2025F 2026F 2027F 2028F 2029F 2030F 2023 2024 2025 2026 2027 2028 2029 2030 Major Markets Patient ($Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Indonesia Patient Size ($Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 % of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Indonesia Market Size ($Bn) 61 74 84 87 91 95 99 106 Illustrative Illustrative 19 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  20. 3.2 Snapshot of Indonesia Pharmaceutical Market Segmentation Molecule Type Therapy Area Prescription Cardiovascular Diseases Prescription Medicines Drug Diabetes OTC Medicines Biologics Respiratory Diseases Cancer Others In this section you will get an understanding of the segmentations which will cover the Indonesia Pharmaceutical Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Illustrative Illustrative 20 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  21. 3.2.1 Market Segmentation: By Therapy Area Indonesia Pharmaceutical Market Share, By Therapy Area (2023) Others Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Cardiovascular Diseases Cancer ▪ ▪ Respiratory Diseases Diabetes Illustrative Illustrative 21 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  22. 3.2.2 Market Segmentation: By Product Type Indonesia Pharmaceutical Market Share, By Product Type (2023) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ ▪ OTC Medicines ▪ Prescription Medicines Illustrative Illustrative 22 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  23. 3.2.3 Market Segmentation: By Molecule Type Indonesia Pharmaceutical Market Share, By Molecule Type (2023) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ ▪ Biologics ▪ Drugs Illustrative Illustrative 23 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  24. Indonesia Pharmaceutical Market Analysis 4. Market Dynamics

  25. 4.1 Snapshot Of Market Growth Drivers And Restraints 4.2.1 4.2.2 Indonesia is experiencing an increase in prevalence of various lifestyle related diseases 4.2.3 Government is implementing various Policies to improve healthcare service availability Increased consumer buying power is primary driver for growing pharmaceutical demand 4.3.1 4.3.2 Lack of human resource and limited Healthcare Infrastructure in rural areas is limiting market potential Local player are Highly dependent on import of Active Pharmaceutical Agent (API) for drug development Illustrative Illustrative 25 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  26. 4.2 Market Growth Drivers 4.2.1 Increased consumer buying power is a primary driver for growing pharmaceutical demand Indonesia per capita Disposable income (2012-2022) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2012 2017 2022 Illustrative Illustrative 26 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  27. 4.2 Market Growth Drivers 4.2.2 Indonesia is experiencing an increase in prevalence of various lifestyle related diseases Prevalence of lifestyle disease in Indonesia (2012-2022) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2012 2017 2022 Illustrative Illustrative 27 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  28. 4.2 Market Growth Drivers 4.2.3 Government is implementing various policies and to improve healthcare service availability Total Healthcare Expenditure as % of GDP (2012-2022) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2012 2017 2022 Illustrative Illustrative 28 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  29. 4.3 Market Growth Restraints 4.3.1 Local player are Highly dependent on import of Active Pharmaceutical Agent (API) for drug development 4.3.2 Lack of human resource and limited Healthcare Infrastructure in rural areas is limiting market potential Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 29 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  30. Indonesia Pharmaceutical Market Analysis 5. Competitive Landscape

  31. 5.1 Key Players in Indonesia Pharmaceutical Market Global Player Here is the list of top 10 companies which will cover in the final report ▪ Local Player 1 6 Each company will have slides for ▪ Sanofi PT Kalbe Farma Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Illustrative Illustrative o o o o 2 7 Novartis PT Sanbe Farma o o o 3 8 GSK PT Dexa Medica o ▪ 4 9 Merck PT Pharos ▪ 10 5 Pfizer PT Indofarma 31 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  32. 5.1.1 Sanofi Offerings Founded In: 1973 ▪ Sanofi is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; vaccines and other products ▪ It has a global presence, with operations in over 150 countries, employs over 87000 people and has a research and development network with over 100 sites worldwide ▪ Sanofi is a leading provider of Pharmaceuticals in Indonesia ➢ Bulk Drug HQ: Paris, France ➢ Vaccines Type: Private Revenue: $46.6 Bn (Global) ➢ Biosimilars Website: www.sanofi.com ➢ OTC Products Recent Activity / Press Coverage ▪ June, 2024 -- Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran ▪ March, 2024 — Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in India ▪ December, 2023 —awareness program in Goa schools to spark lifestyle changes to tackle rising Obesity trend ▪ September, 2023 —Type 1 Diabetes Program by RSSDI supported by Sanofi’s Social Impact Initiative to deliver positive outcomes 32 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  33. 5.1.1 Sanofi (Continued) Latest Deals in Sanofi Company Name Type Year Key Pointers Partnered with Charles River Laboratories International, Inc. to reduce animal usage by replacing control group animals with virtual counterparts from retrospective datasets, promoting ethical research practices Partnered with Belharra Therapeutics to enhance the discovery of novel small-molecule therapeutics for immunological diseases ▪ Partnership June, 2024 ▪ Sanofi acquired Inhibrx Inc. and the drug development project INBRX- 101. Potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency added to Sanofi pipeline Sanofi announced completion of its acquisition of ProventionBio, Inc. The acquisition adds TZIELD (teplizumab-mzwv), an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi core asset portfolio in General Medicines ▪ Acquisition April, 2023 ▪ Illustrative Illustrative 33 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  34. 5.1.1 Sanofi (Continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2023 ▪ 1 2 3 4 Illustrative Illustrative 34 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  35. 5.1.2 Company 2 Offerings Founded In: HQ: Type: Revenue: Website: Recent Activity / Press Coverage Illustrative Illustrative 35 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  36. 5.1.2 Company 2 (Continued) Latest Deals in CompanyName Company Name Type Year Key Pointers Illustrative Illustrative 36 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  37. 5.1.2 Company 2 (Continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2023 ▪ 1 2 3 4 Illustrative Illustrative 37 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  38. Indonesia Pharmaceutical Market Analysis 6. Regulatory and Reimbursement Landscape

  39. 6.1 Regulatory Landscape in Indonesia Regulatory Authorities With Jurisdiction Over Pharmaceuticals In Indonesia Ministry of Health (MOH) oversees public health policy, regulation, and services. It focuses on improving healthcare accessibility, quality, and equity across the nation. The MOH implements programs for disease prevention, health promotion, and emergency response. It also manages the national health insurance scheme, BPJS, and collaborates with international organizations to address public health challenges and enhance the overall health system in Indonesia National Agency of Drug and Food Control (NADFC) is responsible for ensuring the safety, efficacy, and quality of drugs, food, cosmetics, and medical devices. It regulates and supervises the production, distribution, and marketing of these products to protect public health. The NA-DFC conducts inspections, laboratory testing, and enforcement actions against non-compliance. It also provides public education on safe consumption practices and collaborates with international organizations to align with global standards ▪ ▪ Type of Drug registration New drug registration Drug variation registration Re-registration Illustrative Illustrative 39 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  40. 6.2 Reimbursement Scenario in Indonesia Regulatory Framework For The Authorization, And Reimbursement Of Drugs Authorizations, variations, and renewals Reimbursement of Drugs Authorization is valid as long as the pharmaceutical manufacturer continues production and complies with the relevant laws and regulations Ministry of Health oversees reimbursement procedures, ensuring public healthcare access. Offers subsidized or free services, while private insurance reimburses on a fee-for-service basis, aligned with the National List of Essential Medicines ▪ ▪ Pharmaceutical manufacturing authorization includes an authorization to manufacture drugs and/or medicinal substances ▪ Universal Healthcare Program faces challenges bridging coverage gaps ▪ Applicant shall submit all the changes to the director-general of pharmaceuticals at the Ministry of Health ▪ Private insurers cater to high-income groups with partial expense coverage ▪ Illustrative Illustrative 40 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  41. 6.2 Reimbursement Scenario in Indonesia (Continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure xx 46.0% xx 47.7% xx xx xx 51.0% 51.8% Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2019 2020 2021 2022 2023 2017 2018 2019 2020 2021 2022 2023  Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid  Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in Indonesia healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 41 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  42. 6.3 Reimbursement Process The reimbursement process in Indonesia healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost of the service, such as deductibles, co-payments, or co-insurance In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 42 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  43. 6.3 Reimbursement Process (Continued) The reimbursement process in Indonesia healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: MoH Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Market Authorization Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Private Payers Public Payers Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Health Technology Assessment Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ 1 2 3 Coding Coverage Payment Coding depends on availability code while coverage and payment process decisions are made through an HTA. Illustrative Illustrative 43 A Sample Report on Indonesia Pharmaceutical Market Analysis I Confidential

  44. A division of

  45. Life-sciences Market Research Reports you can trust We maintain an extensive database comprising over 30,000 syndicated market research reports within the pharmaceuticals and healthcare sector, offering a global, regional, and country-level perspective. Our services also include the provision of customized research reports, meticulously tailored to align with your specific requirements. www.insights10.com www.insights10.com

  46. Pharma (Diseases & Drugs) Digital Health Market Research Reports across various categories in healthcare OTC & Medical Devices Nutraceuticals At Insights10, our extensive report library spans a diverse range of categories within the field of life sciences. Clinical Trials Healthcare Services Rare Diseases www.insights10.com www.insights10.com

  47. Global Coverage Europe • UK • Germany • France • Italy • Spain • Russia • Netherlands • Sweden • Romania • Switzerland • Poland • Austria • Ireland • Norway • Denmark • Belgium • Portugal • Ukraine • Bulgaria • Finland APAC • India • China • South Korea • Japan • Australia • Indonesia • Hong Kong • New Zealand • Philippines • Singapore • Malaysia • Thailand • Vietnam North America • US • Canada Africa • Egypt • Kenya • South Africa • Algeria • Nigeria • Libya • Tanzania • Morocco Middle East • UAE • Saudi Arabia • Turkey • Lebanon • Kuwait • Qatar Latin America • Brazil • Argentina • Mexico • Ecuador • Venezuela • Senegal Click on the country to see the reports available

  48. What do our reports cover? Market Overview Competitive Landscape 1 6 Growth Drivers & Growth Restraints 2 7 Policy & Regulatory Landscape Epidemiology & Disease type 3 8 Reimbursement Scenario Market Size & Forecast Recent Developments 4 9 Market Segmentation Factors Driving Future Growth 5 10

  49. Our Research Process 01 02 03 04 05 06 Define precise research questions Gather data through secondary research Validate data through primary research interviews Forecast market size and segment analysis Extract key insights from the research findings Compile & present a comprehensive analytical report

  50. Data Triangulation & Data Validation Top Down Approach Find final Examine the total healthcare expenditure in the targeted disease or service domain. market size Assess the proportion of spending allocated to the specific product or treatment category. Predict future market growth or decline based on key market trends & dynamics Predict future market growth or decline based on key market trends & dynamics Analyze product or treatment pricing and reimbursement strategies Find final market size Evaluate consumer or patient demographics and numbers Bottom Up Approach

More Related